These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9137882)

  • 1. Two novel mutations in a Canadian family with aspartylglucosaminuria and early outcome post bone marrow transplantation.
    Laitinen A; Hietala M; Haworth JC; Schroeder ML; Seargeant LE; Greenberg CR; Aula P
    Clin Genet; 1997 Mar; 51(3):174-8. PubMed ID: 9137882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of mutations in aspartylglucosaminuria.
    Ikonen E; Aula P; Grön K; Tollersrud O; Halila R; Manninen T; Syvänen AC; Peltonen L
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11222-6. PubMed ID: 1722323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
    Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
    Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Origin of Finnish mutations causing aspartylglucosaminuria.
    Valkonen S; Hietala M; Savontaus ML; Aula P
    Hereditas; 1999; 131(3):191-5. PubMed ID: 10783529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
    Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
    J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.
    Ikonen E; Peltonen L
    Hum Mutat; 1992; 1(5):361-5. PubMed ID: 1301945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convenient and quantitative determination of the frequency of a mutant allele using solid-phase minisequencing: application to aspartylglucosaminuria in Finland.
    Syvänen AC; Ikonen E; Manninen T; Bengtström M; Söderlund H; Aula P; Peltonen L
    Genomics; 1992 Mar; 12(3):590-5. PubMed ID: 1559710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
    Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
    Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartylglucosaminuria in a Canadian family.
    Gordon BA; Rupar CA; Rip JW; Haust MD; Coulter-Mackie MB; Scott E; Hinton GG
    Clin Invest Med; 1998 Jun; 21(3):114-23. PubMed ID: 9627765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and structural insights into an allelic variant causing the lysosomal storage disorder - aspartylglucosaminuria.
    Pande S; Bizilj W; Guo HC
    FEBS Lett; 2018 Aug; 592(15):2550-2561. PubMed ID: 29993127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspartylglucosaminuria in northern Norway: a molecular and genealogical study.
    Tollersrud OK; Nilssen O; Tranebjaerg L; Borud O
    J Med Genet; 1994 May; 31(5):360-3. PubMed ID: 8064811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.
    Ikonen E; Enomaa N; Ulmanen I; Peltonen L
    Genomics; 1991 Sep; 11(1):206-11. PubMed ID: 1765378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of three alleles causing aspartylglycosaminuria: two from a British family and one from an American patient.
    Park H; Vettese MB; Fensom AH; Fisher KJ; Aronson NN
    Biochem J; 1993 Mar; 290 ( Pt 3)(Pt 3):735-41. PubMed ID: 8457202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
    Saarela J; von Schantz C; Peltonen L; Jalanko A
    Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
    Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
    Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspartylglucosaminuria among Palestinian Arabs.
    Zlotogora J; Ben-Neriah Z; Abu-Libdeh BY; Sury V; Zeigler M
    J Inherit Metab Dis; 1997 Nov; 20(6):799-802. PubMed ID: 9427148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissection of the molecular consequences of a double mutation causing a human lysosomal disease.
    Riikonen A; Ikonen E; Sormunen R; Lehto VP; Peltonen L; Jalanko A
    DNA Cell Biol; 1994 Mar; 13(3):257-64. PubMed ID: 8172656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartylglycosaminuria: biochemistry and molecular biology.
    Aronson NN
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):139-54. PubMed ID: 10571008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.